PARSIPPANY, N.J.--(BUSINESS WIRE)--Teva Pharmaceuticals USA, Inc., an affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that the autoinjector device for AJOVY ® ...

PARSIPPANY, N.J.--(BUSINESS WIRE)-- Teva Pharmaceuticals USA, Inc. an affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that the Food and Drug Administration (FDA) ...

After its auto-injector approval earlier this year, sales for Teva's Ajovy are picking up. (Teva) () Upon its FDA approval in 2018, Teva’s migraine prevention medicine Ajovy faced tough prospects as ...

On Jan. 29, the Food and Drug Administration approved Teva Pharmaceutical’s (NYSE:TEVA) auto-injector device for use with its Ajovy calcitonin gene-related peptide migraine prevention drug. That news ...

Teva Canada launches new Autoinjector for Ajovy to prevent migraine in adults AJOVY now offers patients greater flexibility with two dosing options available in both an autoinjector and a prefilled ...

Ajovy (fremanezumab-vfrm; Teva) is now available in an autoinjector device for the preventive treatment of migraine in adults. Ajovy (fremanezumab-vfrm; Teva) is now available in an autoinjector ...

The primary efficacy endpoint was the mean change from baseline in the monthly average number of headache days of at least moderate severity during the 3-month treatment period. Teva announced that ...

Teva Pharmaceutical Industries Ltd. today announced that the U.S. Food and Drug Administration (FDA) has approved AJOVY TM (fremanezumab-vfrm) injection for the preventive treatment of migraine in ...